AOP Orphan Pharmaceuticals Aktiengesellschaft
AOP Orphan Pharmaceuticals Aktiengesellschaft
Contact:
AOP
Phone: +43 503 72 44 24
E-Mail: nina.roth@aoporphan.com
KEYWORDS:
  • Polycythaemia Vera
  • BESREMi
  • Ropeginterferon
  • AOP Orphan
  • PharmaEssentia
Download Photos
AOP Orphan Pharmaceuticals Aktiengesellschaft (21 releases)

Today the Higher Regional Court of Frankfurt declared enforceable the October 2020 award pertaining to the arbitration between AOP Orphan and PharmaEssentia Corp. The agreement between AOP Orphan and PharmaEssentia Corp.remains in full force and effect, and AOP Orphan is entitled to damages from PharmaEssentia of approx. EUR 142 million. [more]

AOP Orphan announces positive CHMP opinion for Ropeginterferon alfa-2b/BESREMi®
2018-12-17, pts20181217010 Science/Technology, Health/Medicine
AOP Orphan announces positive CHMP opinion for Ropeginterferon alfa-2b/BESREMi®
2018-12-17, pts20181217008 Science/Technology, Health/Medicine
AOP Orphan announces three-year results on Ropeginterferon alfa-2b in Polycythemia Vera at ASH
2018-12-03, pts20181203046 Health/Medicine, Products/Innovations
AOP Orphan and Bioprojet Pharma SAS entered a distribution agreement for Wakix®
2018-03-22, pts20180322023 Products/Innovations, Science/Technology
AOP Orphan announces two-year results on Ropeginterferon alfa-2bin PV
2017-12-10, pts20171210001 Health/Medicine, Science/Technology
AOP Orphan Pharmaceuticals AG to acquire Selisistat
2017-10-02, pts20171002022 Products/Innovations, Health/Medicine
AOP Orphan and PharmaEssentia announce latest clinical results for Ropeginterferon alfa-2b in PV
2017-06-25, pts20170625010 Products/Innovations, Health/Medicine
AOP Orphan starts EMA marketing authorization application procedure for Ropeginterferon alfa-2b
2017-03-14, pts20170314029 Health/Medicine, Products/Innovations

1 2 3 Next »